Member Info for Aldebaran

Link nit working Hurst can you post the content

The thing with ava6k is that you put it in the body and it flows around in the blood clearing up any metastasis as well.

Chemo is also the cheapest form of treatment in a world where cost comes into healthcare this is very important

CAn anyone explain why we need to see where fap is in the body? We know FAp is highly upregulated in tumours and we can find tumours with normal cat scans so what is the point in developing tech to find FAP?

Price is still 30% above placing price

Why should any new investor or trader want to buy knowing anyone who took part in the placing has 30% advantage and will dump their stock as soon as the shares land.

Nope. No no no for me and to think Justin as pumping this at a quid not so long ago

And at what discount

Ok Chris

Is this what big p want to see

There was a lady on twitter working for Novartis who said something like avacta have done the hard part proving safety and now just have to prove efficacy but "thats not rocket science" can anyone remember what I'm.talking about so surely

My point is surely once 2week data is here then its all eyes on an offer. And from what people are saying that 2week data isn't too far away

People are saying they'd take 3 quid now but that's sentiment talking. All we need is the SP to start moving and the dreams of 10pound plus will be alive again.

Its all relative.

Ultimately the TO will happen and our votes won't count for much in the scheme of things.

You can't go wrong at this price without some kind of absolute disaster happening. Unlikely.

If we get back to 1pound per share 3pound will once again be laughed at.

When do we expect results from 2 week study

"Cant buy" haha

"wouldn't be out this at the weekend"

"Mm want your shares"

Meanwhile SP is on its knees and peptide drug conjugates are the hottest thing in town

Took more risk off the table here

All these people saying they're buying yet the SP shows you what people are actually doing

Let us remember that avactas ava6000 doesn't need to be a success at 2weekly dosing. It just needs to be marginally better than straight dox dosed every 3 weeks and it takes billions in sales over next few years simples.

Of course we all want the 2weekly to smash it out the park as its better for patients and of course will put precision into an exceptional category so yes we want it but its not necessary to make a lot of money on this share is what I'm saying.

People need to chil

You can't have a blow by blow account just let them get on with it

Wasn't done properly @ on here yesterday saying weak close means doom today as well. Honestly there is some right mu pp ets that frequent this chat

Expecting this to move north rapidly soon.

Sellers look exhausted and has to hit a turning point sometime. Just hope GSA and others manage to close their short for a nice profit and don't have to panic buy the shares back at a loss.

NOT

Sadly not much I imagine polx have practically given it away like any new business would when first starting out. Got to generate customers etc..

Company still need funding. Probably right after next fundraise if more sales come and market cap still in reasonable price then buy then otherwise its expensive to just sit on these shares

After all this time

Just what is happening here clearly nobody interested

Inline is as good as a warning in this market.

Still a real lack of insider buys and company not profitable.

Will they make any money before the whole bubble bursts and let's face it thats what this is

Even if Q2W isn't very good remember that it doesn't even need to be.

Ava6thousand just needs to be safer than straight doxorubicin to replace it as standard of care. Theres over 1bn in sales right there in just a couple of years. That alone makes Avacta a 5bn company and what are the chances of it happening? I think its a formality now.

Wyn is trading you can tell by the change in tone from post to post depending on his position. Either that or he is by polar. Upto him he is running the risk of being OUT when the RNS lands and it can come out the blue so he'll either be very lucky or will look very very stupid with the odd 10pc here or there over the years when he could have made a life changing amount

Market got wind of this change and has responded well already.

Finance in place now and CEO brought in to drive commercialisation. Lot to like in that update.

What if they give clear indication Qw2 is going exceptionally well.

I'm sure there will be something in this update to send our valuation back up